Evaluation of Patients' Preferences for Triamcinolone Acetonide Aqueous, Fluticasone Propionate, and Mometasone Furoate Nasal Sprays in Patients with Allergic Rhinitis

Abstract

OBJECTIVE: To compare product attributes, preferences, and expected compliance associated with triamcinolone acetonide aqueous (TAA-AQ), fluticasone propionate (FP), and mometasone furoate (MF) nasal sprays in patients with allergic rhinitis. STUDY DESIGN AND SETTING: Data from 2 randomized, double-blind crossover studies with identical design were pooled (N = 215). Patients completed a 14-item sensory attributes questionnaire immediately after each product, and stated their preference and expected compliance with a prescription after receiving all products. RESULTS: Compared with FP and MF, TAA-AQ was associated with significantly less odor and greater liking of odor ( P < 0.001); and less taste, less dryness of nose/throat, less aftertaste, and greater overall liking ( P < 0.05). Significantly more patients preferred most a prescription of TAA-AQ (50.0%) versus FP (25.0%; P < 0.001) and MF (25.0%; P < 0.001), and would “definitely comply” with TAA-AQ (62.5%) versus FP (49.0%; P < 0.01) and MF (51.0%; P < 0.01). CONCLUSION: TAA-AQ was associated with significantly more positive sensory attributes, higher preference, and better expected compliance than FP and MF. SIGNIFICANCE: Patients' preferences for the sensory attributes of an intranasal corticosteroid may affect adherence to treatment.